A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III

Silvia Monticone, Namita G. Hattangady, David Penton, Carlos M Isales, Michael A. Edwards, Tracy A. Williams, Christina Sterner, Richard Warth, Paolo Mulatero, William E. Rainey

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Context: Primary aldosteronism is a heterogeneous group of disorders comprising both sporadic and familial forms. Mutations in the KCNJ5 gene, which encodes the inward rectifier K+ channel 4 (G protein-activated inward rectifier K+ channel 4, Kir3.4), cause familial hyperaldosteronism type III (FH-III) and are involved in the pathogenesis of sporadic aldosterone-producing adenomas. Objective: The objective of the study was to characterize the effects of a newly described KCNJ5 mutation in vitro. Patients and Methods: The index case is a 62-year-old woman affected by primary aldosteronism, who underwent left adrenalectomy after workup for adrenal adenoma. Exon 1 of KCNJ5 was PCR amplified from adrenal tissue and peripheral blood and sequenced. Electrophysiological and gene expression studies were performed to establish the functional effects of the new mutation on the membrane potential and adrenal cell CYP11B2 expression. Results: KCNJ5 sequencing in the index case revealed a new p.Y152C germline mutation; interestingly, the phenotype of the patient was milder than most of the previously described FH-III families. The tyrosine-to-cysteine substitution resulted in pathologicalNa+permeability, cellmembrane depolarization, and disturbed intracellular Ca2+ homeostasis, effects similar, albeit smaller, to the ones demonstrated for other KCNJ5 mutations. Gene expression studies revealed an increased expression of CYP11B2 and its transcriptional regulator NR4A2 in HAC15 adrenal cells overexpressing KCNJ5 Y152C compared to the wild-type channel. The effect was clearly Ca2+-dependent, because it was abolished by the calcium channel blocker nifedipine. Conclusions: Herein we describe a new germline mutation in KCNJ5 responsible for FH-III.

Original languageEnglish (US)
JournalJournal of Clinical Endocrinology and Metabolism
Volume98
Issue number11
DOIs
StatePublished - Nov 1 2013

Fingerprint

Cytochrome P-450 CYP11B2
Inwardly Rectifying Potassium Channel
Gene expression
Mutation
Hyperaldosteronism
Germ-Line Mutation
Depolarization
Calcium Channel Blockers
Nifedipine
Aldosterone
GTP-Binding Proteins
Adenoma
Cysteine
Tyrosine
Exons
Blood
Substitution reactions
Genes
Tissue
Membranes

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. / Monticone, Silvia; Hattangady, Namita G.; Penton, David; Isales, Carlos M; Edwards, Michael A.; Williams, Tracy A.; Sterner, Christina; Warth, Richard; Mulatero, Paolo; Rainey, William E.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 98, No. 11, 01.11.2013.

Research output: Contribution to journalArticle

Monticone, S, Hattangady, NG, Penton, D, Isales, CM, Edwards, MA, Williams, TA, Sterner, C, Warth, R, Mulatero, P & Rainey, WE 2013, 'A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III', Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 11. https://doi.org/10.1210/jc.2013-2428
Monticone, Silvia ; Hattangady, Namita G. ; Penton, David ; Isales, Carlos M ; Edwards, Michael A. ; Williams, Tracy A. ; Sterner, Christina ; Warth, Richard ; Mulatero, Paolo ; Rainey, William E. / A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. In: Journal of Clinical Endocrinology and Metabolism. 2013 ; Vol. 98, No. 11.
@article{263db75fdcc74c65a1c8d888b04fdb8f,
title = "A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III",
abstract = "Context: Primary aldosteronism is a heterogeneous group of disorders comprising both sporadic and familial forms. Mutations in the KCNJ5 gene, which encodes the inward rectifier K+ channel 4 (G protein-activated inward rectifier K+ channel 4, Kir3.4), cause familial hyperaldosteronism type III (FH-III) and are involved in the pathogenesis of sporadic aldosterone-producing adenomas. Objective: The objective of the study was to characterize the effects of a newly described KCNJ5 mutation in vitro. Patients and Methods: The index case is a 62-year-old woman affected by primary aldosteronism, who underwent left adrenalectomy after workup for adrenal adenoma. Exon 1 of KCNJ5 was PCR amplified from adrenal tissue and peripheral blood and sequenced. Electrophysiological and gene expression studies were performed to establish the functional effects of the new mutation on the membrane potential and adrenal cell CYP11B2 expression. Results: KCNJ5 sequencing in the index case revealed a new p.Y152C germline mutation; interestingly, the phenotype of the patient was milder than most of the previously described FH-III families. The tyrosine-to-cysteine substitution resulted in pathologicalNa+permeability, cellmembrane depolarization, and disturbed intracellular Ca2+ homeostasis, effects similar, albeit smaller, to the ones demonstrated for other KCNJ5 mutations. Gene expression studies revealed an increased expression of CYP11B2 and its transcriptional regulator NR4A2 in HAC15 adrenal cells overexpressing KCNJ5 Y152C compared to the wild-type channel. The effect was clearly Ca2+-dependent, because it was abolished by the calcium channel blocker nifedipine. Conclusions: Herein we describe a new germline mutation in KCNJ5 responsible for FH-III.",
author = "Silvia Monticone and Hattangady, {Namita G.} and David Penton and Isales, {Carlos M} and Edwards, {Michael A.} and Williams, {Tracy A.} and Christina Sterner and Richard Warth and Paolo Mulatero and Rainey, {William E.}",
year = "2013",
month = "11",
day = "1",
doi = "10.1210/jc.2013-2428",
language = "English (US)",
volume = "98",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III

AU - Monticone, Silvia

AU - Hattangady, Namita G.

AU - Penton, David

AU - Isales, Carlos M

AU - Edwards, Michael A.

AU - Williams, Tracy A.

AU - Sterner, Christina

AU - Warth, Richard

AU - Mulatero, Paolo

AU - Rainey, William E.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Context: Primary aldosteronism is a heterogeneous group of disorders comprising both sporadic and familial forms. Mutations in the KCNJ5 gene, which encodes the inward rectifier K+ channel 4 (G protein-activated inward rectifier K+ channel 4, Kir3.4), cause familial hyperaldosteronism type III (FH-III) and are involved in the pathogenesis of sporadic aldosterone-producing adenomas. Objective: The objective of the study was to characterize the effects of a newly described KCNJ5 mutation in vitro. Patients and Methods: The index case is a 62-year-old woman affected by primary aldosteronism, who underwent left adrenalectomy after workup for adrenal adenoma. Exon 1 of KCNJ5 was PCR amplified from adrenal tissue and peripheral blood and sequenced. Electrophysiological and gene expression studies were performed to establish the functional effects of the new mutation on the membrane potential and adrenal cell CYP11B2 expression. Results: KCNJ5 sequencing in the index case revealed a new p.Y152C germline mutation; interestingly, the phenotype of the patient was milder than most of the previously described FH-III families. The tyrosine-to-cysteine substitution resulted in pathologicalNa+permeability, cellmembrane depolarization, and disturbed intracellular Ca2+ homeostasis, effects similar, albeit smaller, to the ones demonstrated for other KCNJ5 mutations. Gene expression studies revealed an increased expression of CYP11B2 and its transcriptional regulator NR4A2 in HAC15 adrenal cells overexpressing KCNJ5 Y152C compared to the wild-type channel. The effect was clearly Ca2+-dependent, because it was abolished by the calcium channel blocker nifedipine. Conclusions: Herein we describe a new germline mutation in KCNJ5 responsible for FH-III.

AB - Context: Primary aldosteronism is a heterogeneous group of disorders comprising both sporadic and familial forms. Mutations in the KCNJ5 gene, which encodes the inward rectifier K+ channel 4 (G protein-activated inward rectifier K+ channel 4, Kir3.4), cause familial hyperaldosteronism type III (FH-III) and are involved in the pathogenesis of sporadic aldosterone-producing adenomas. Objective: The objective of the study was to characterize the effects of a newly described KCNJ5 mutation in vitro. Patients and Methods: The index case is a 62-year-old woman affected by primary aldosteronism, who underwent left adrenalectomy after workup for adrenal adenoma. Exon 1 of KCNJ5 was PCR amplified from adrenal tissue and peripheral blood and sequenced. Electrophysiological and gene expression studies were performed to establish the functional effects of the new mutation on the membrane potential and adrenal cell CYP11B2 expression. Results: KCNJ5 sequencing in the index case revealed a new p.Y152C germline mutation; interestingly, the phenotype of the patient was milder than most of the previously described FH-III families. The tyrosine-to-cysteine substitution resulted in pathologicalNa+permeability, cellmembrane depolarization, and disturbed intracellular Ca2+ homeostasis, effects similar, albeit smaller, to the ones demonstrated for other KCNJ5 mutations. Gene expression studies revealed an increased expression of CYP11B2 and its transcriptional regulator NR4A2 in HAC15 adrenal cells overexpressing KCNJ5 Y152C compared to the wild-type channel. The effect was clearly Ca2+-dependent, because it was abolished by the calcium channel blocker nifedipine. Conclusions: Herein we describe a new germline mutation in KCNJ5 responsible for FH-III.

UR - http://www.scopus.com/inward/record.url?scp=84887447941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887447941&partnerID=8YFLogxK

U2 - 10.1210/jc.2013-2428

DO - 10.1210/jc.2013-2428

M3 - Article

VL - 98

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -